Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia (Q36333136)

13 August 2017

1 reference

title

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia (English)

1 reference

13 August 2017

0 references

1 reference

Robert J Cersosimo

1

1 reference

13 August 2017

Daniel R Jacobson

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

6 December 2005

1 reference

Annals of Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

40

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

58-65; quiz 169-70

1 reference

Clinical and economic comparison of epoetin alfa and darbepoetin alfa

13 August 2017

cites work

1 reference

Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations

21 January 2018

1 reference

Development and characterization of novel erythropoiesis stimulating protein (NESP)

21 January 2018

1 reference

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

21 January 2018

1 reference

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.

21 January 2018

1 reference

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

21 January 2018

1 reference

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease

21 January 2018

1 reference

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G042

1 reference

13 August 2017

1 reference